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ABSTRACT 
Background & Aims:  
Up to 40% of patients with severe alcoholic hepatitis (AH) die within 6 months of presentation 
making prompt diagnosis and appropriate treatment essential. We determined the associations 
between serum keratin-18 (K18) and histological features, prognosis and differential response to 
prednisolone, in patients with severe AH. 
Approach & Results:  
Total (K18-M65) and caspase-cleaved K18 (K18-M30) were quantified in pre-treatment sera from 
824 patients enrolled in the STOPAH trial (87 with suitable histological samples) and disease 
controls. K18 fragments were markedly elevated in severe AH and strongly predicted 
steatohepatitis (ASH) on biopsy (area under receiver operating characteristics: 0.787 and 0.807). 
Application of published thresholds to predict ASH would have rendered biopsy unnecessary in 
84% of all AH cases. K18-M30 and M65 were associated with 90-day mortality independently of 
age and Model for End-stage Liver Disease (MELD) score in untreated patients. The association 
for K18-M65 was independent of both age and MELD in prednisolone treated patients. Modelling 
of the effect of prednisolone on ninety-day mortality as a function of pre-treatment serum K18 
levels indicated benefit in those with high serum levels of K18-M30. At low pre-treatment serum 
K18 levels prednisolone was potentially harmful. A threshold of K18-M30 5 kIU/L predicted 
therapeutic benefit from prednisolone above this level (Odds Ratio: 0.433, 95% Confidence 
Interval: 0.19-0.95, p=0.0398), but not below (OR 1.271, 95% CI 0.88 – 1.84, p=0.199). Restricting 
prednisolone usage to the former group would have reduced exposure by 87%. 
Conclusions:  
In a large cohort of patients with severe AH, serum K18 strongly correlated with histological 
severity, independently associated with 90-day mortality and predicted response to prednisolone 
therapy. Quantification of serum K18 levels could assist clinical decision-making. 
Keywords: liver disease, K18, prednisolone, alcohol, steroids, alcoholic hepatitis 
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STUDY HIGHLIGHTS 
WHAT IS KNOWN 
Severe alcoholic hepatitis is associated with significant mortality 
Definite diagnosis requires liver biopsy 
Prednisolone treatment is associated with complications 
Robust diagnostic, prognostic and theragnostic biomarkers are lacking 
K18 fragments are promising diagnostic and prognostic markers in liver disease 
Conclusive data is needed for application in severe alcoholic hepatitis 
 
WHAT IS NEW HERE 
In patients with the clinical syndrome of severe alcoholic hepatitis: 
Serum K18 fragments predict ASH and severe inflammation on biopsy 
Serum K18-M65 predicts 90-day mortality, independently of MELD score 
Prednisolone may only benefit where K18-M30 exceeds 5 kIU/L 
K18 measurement could reduce biopsy rates and prednisolone exposure 
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Introduction 
Alcoholic hepatitis (AH) is a clinical syndrome characterized by the rapid onset of jaundice and 
liver failure in patients with active chronic, heavy alcohol misuse(1). Up to 40% of patients with 
severe alcoholic hepatitis, defined as a Maddrey’s discriminant function (DF) >32(2), die within 6 
months of presentation making prompt diagnosis and appropriate treatment essential(3). A 
number of algorithms have been used to predict outcomes in severe AH including DF(2), the 
Glasgow AH score (GAHS)(4) and the Age-Bilirubin-INR-Creatinine (ABIC) score(5); all of these 
have modest performance characteristics in assessing short-term mortality(6). The model for end-
stage liver disease (MELD) score has been used with varying cut-off values between studies, but, 
performs best when used as a continuous variable in individual patients(6). Notably, the correlation 
between these scoring systems and the histopathological features of alcoholic steatohepatitis 
(ASH) remains poor(7). The latter include hepatocyte ballooning, neutrophil infiltration and 
Mallory-Denk bodies. A histologic scoring system has been developed that independently 
correlates with 90-day mortality(8). However, a combination of expense, practicality and 
availability often mean it is not feasible to perform liver biopsy(9). 
Acute hepatocellular injury in AH results in necrosis and apoptosis. This is likely secondary to 
increased gastrointestinal permeability with translocation of bacterial products into the portal and 
systemic circulation with an intense inflammatory reaction resulting from both processes(10). 
These acute events take place in a setting of pre-existing chronic liver disease with a variable 
amount of liver fibrosis and consequently decreased hepatocellular reserve. Correspondingly, out 
of the commonly analyzed histological features, the presence of bridging liver fibrosis constitutes 
the strongest negative prognostic marker, while severe neutrophil infiltration and occurrence of 
megamitochondria are signs associated with more favorable outcomes(8). Prior data indicate that 
marked neutrophilic infiltration confers a better prognosis in prednisolone-treated patients(11) 
suggesting that those with the most severe acute, inflammatory disease might benefit most from 
immunosuppressive treatments. 
9 
 
9 
 
 
Hepatocellular injury markers are routinely used in the diagnosis of severe AH. AST levels above 
50 IU/L and AST:ALT ratio >1.5 are considered diagnostic for AH although levels are generally 
below 400 IU/L(9). Keratin-18 (K18) is an abundant, cytoplasmic protein expressed in glandular 
and single-layered epithelia(12, 13). Serum levels of K18 fragments have been widely used as 
markers of hepatocellular death(14, 15). The M65 antibody detected protein reflects total cell 
death, whilst the M30 antibody detected fragment is generated when K18 is cleaved during 
apoptosis(14). K18 fragment serum levels have been shown to be markedly elevated in the serum 
of AH patients, and their ability to distinguish them from healthy controls and individuals with 
alcoholic cirrhosis indicates diagnostic utility(7, 16). Moreover, in multiple liver disorders such as 
ALD, NAFLD or chronic hepatitis C infection(17-19), K18 serum fragments mirrored the extent of 
histological disease activity. 
Corticosteroids are the first line treatment option in severe AH(1). However, their use only confers 
a minor improvement in 28-day mortality(20-22). Furthermore, steroids carry a risk of severe 
adverse events, in particular they predispose to the development of infection(23, 24). 
Consequently careful patient selection is required to ensure those treated derive benefit and 
others are not unduly exposed to the risk of infection, especially when liver transplantation remains 
a potential treatment option(25). 
We hypothesized that the degree of acute hepatocellular injury and inflammation might determine 
the prognosis of AH patients and identify individuals who will benefit from corticosteroid therapy. 
To test this hypothesis, we determined the relationship between serum K18 fragments and 
histological features, outcome and response to prednisolone in participants recruited to the 
Steroids or Pentoxifylline for Alcoholic Hepatitis (STOPAH) clinical trial (ISRCTN:88782125).  
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METHODS 
Study populations 
Cases with severe alcoholic hepatitis were recruited via the STOPAH trial as per the trial 
protocol(26, 27), (Supplemental Information). Patients were randomised to treatment with 
prednisolone or pentoxifylline for 28 days using a double-blind, double-dummy factorial 2 x 2 
design. Outcome data were collected for mortality at 28 and 90 days. Ethical approval was granted 
for this study by the Wales Research Ethics Committee (REC 09/MRE09/59). Patients with 
alcoholic cirrhosis recruited to the prospective longitudinal ‘Compensated Cirrhosis Cohort in 
Nottingham study (Ref 10/H0403/10; approved by East Midlands Nottingham 1 ethics committee) 
were used as an additional control group (Supplemental Information). The study was conducted 
according to the Declaration of Helsinki (Hong Kong Amendment) and Good Clinical Practice 
(European guidelines). All participants, or their legally-appointed representatives, provided written 
informed consent.  
Measurement of laboratory parameters 
Clinical data were recorded at the baseline visit. Pre-treatment serum samples were available 
from 866 patients. Sufficient serum was available for quantification of K18-M65 and K18-M30 by 
ELISA (VLVbio, Stockholm, Sweden) in 824 (95%). Estimation was performed according to the 
manufacturer’s instruction, samples with high values outside the standard curve were reassessed 
after dilution in ‘Buffer A’. AST was determined in serum from patients where clinical data was 
unavailable as detailed in Supplemental Information. 
Histological analyses 
Two experienced histopathologists (RG and AQ), blinded to patient treatment and outcomes, 
independently assessed the histological features of each biopsy using the alcoholic hepatitis 
histological scoring system (AHHS)(8), fibrosis was graded using the Laennec system(28) 
(Supplementary Table 1). The presence or absence of Mallory-Denk bodies and 
megamitochondria was also recorded. 
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Data processing and statistical analysis 
MELD(29) and DF prognostic scores were derived in accordance with their original 
descriptions(30). Statistical analyses were conducted in R (R Foundation, Vienna, Austria) using 
‘DescTools’, ‘dplyr’, ‘qwraps2’, ‘pROC’, ‘OptimalCutpoints’, ‘ggplot2’, ‘survival’ and ‘psych’. 
Specific statistical tests used for baseline data analysis are detailed in Supplemental Information. 
Mortality associations 
To provide independent populations for mortality association testing the cohort was split into 
exploratory and validation groups based upon the trial’s random assignment to receive 
prednisolone. This approach was chosen in order to i) leverage the original randomization 
structure which incorporated factors including baseline risk and recruiting centre, and ii) 
demonstrate validity of associations with and without prednisolone treatment. Several studies and 
meta-analyses have failed to demonstrate an effect of pentoxifylline on 28-day or subsequent 
mortality either alone or in combination with prednisolone, consequently pentoxifylline treatment 
was not incorporated into statistical modelling. Ninety-day mortality was considered the primary 
outcome with death at 28 days used in secondary analyses. Logistic regression was used to test 
for associations with either 28- or 90-day mortality. Multivariate models were specified including 
the MELD score and age as covariates. AUROC analysis was used to assess predictive 
performance. Models combining the MELD and serum biomarkers were generated using logistic 
regression analysis and leave one out 10-fold cross validation in the exploratory cohort in order to 
avoid over-optimism; the model generated was subsequently tested in the validation cohort. 
Interaction testing 
To detect any influence of K18 on prednisolone efficacy, we performed interaction testing in the 
entire cohort (Supplemental Information). To explore the implied relationship between 
prednisolone, K18 and mortality, the adjusted interaction models were used to generate 90-day 
mortality risks with, and without, prednisolone across a range of K18 values. Age and MELD were 
set at the mean values for the overall dataset. Plots were generated estimating the effect of 
prednisolone across the range of K18 values, candidate cut-offs were selected based upon 
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maximal divergence of the confidence intervals of prednisolone effect in those above and below 
the selected level. Survival curves were generated to illustrate the differences in outcome between 
populations defined by any cut-off and prednisolone treatment status. The same methodology was 
applied to detect interactions between the Lille score and prednisolone in relation to mortality. 
Infection associations 
Prednisolone administration has previously been associated with an excess of infection, including 
in this cohort. Severe infection was defined as previously described(24, 27). The association 
between prednisolone and severe infection was tested using logistic regression. Analyses were 
additionally adjusted for age and MELD score.  
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RESULTS 
Composition of the study cohort and serum K18 levels 
The 824 individuals from the STOPAH cohort included in this study had similar baseline 
characteristics (Table 1) to those previously described for the full trial cohort(27). ALT levels were 
within the normal range or only slightly increased, whereas AST was typically twice or three times 
higher than the upper limit of normal(31). Serum K18 fragments were successfully quantified in 
814/824 (98.8%) cases. Serum K18-M30 values ranged from 125 to 82660 IU/L, the median value 
was 1812.78, at least seven times higher than the values typically seen in healthy individuals. 
K18-M65 values ranged from 296 to 71852 IU/L, with a median of 4381, i.e. >10 times higher than 
the 95% percentile defined for the normal population(32). 
In the control group of patients with alcoholic cirrhosis including compensated (n=76) and 
decompensated cirrhosis (n=10), K18-M30 levels ranged from 31 to 989 IU/L and K18-M65 
ranged 24 to 1968 (Supplementary Table 2). The ratio of K18-M30 to K18-M65 was calculated 
and ranged from 0.1 to 1.55, the median was 0.45.  
In view of their magnitude values are reported as kIU/L (1 kIU/L= 1000 IU/L). 
Histological analyses 
In total, 87 liver biopsy samples from patients with serum K18 measurements were eligible for 
histological analyses. In 79 cases (91%) there was a definite histological diagnosis of alcoholic 
steatohepatitis (ASH). The biopsy cohort demonstrated similar baseline characteristics to the 
overall cohort though with somewhat lower 90-day mortality (Table 1). 
Increasing Laennec fibrosis stage was associated with decreasing serum K18-M30 (p=0.00523) 
and K18-M65 (p=0.00207) (Figure 1a-b). K18-M30 and K18-M65 levels were significantly greater 
in cases with severe inflammation on biopsy (both p<0.0001) and marked hepatocyte ballooning 
(M30: p=0.000431, M65: p=0.000675; Figure 1c-f). Cases where Mallory-Denk body formation 
was observed also disclosed significantly higher K18-M30 (median: 2.82 kIU/L (IQR: 1.15 – 4.54) 
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vs. 1.04 kIU/L (0.80 – 1.77), p=0.000149) and K18-M65 (5.98 kIU/L (3.86 – 8.36) vs. 2.77 kIU/L 
(2.00 – 4.87), p<0.0001; Supplementary Figure 1a-b). 
The M30:M65 ratio was significantly higher in cases with severe inflammation (0.49 (0.41 – 0.63 
vs. 0.42 (0.35 – 0.54), p=0.0400; Supplementary Figure 2b). However, it did not differ significantly 
in groups defined by Laennec fibrosis stage (p=0.510), the presence of marked hepatocyte 
ballooning (0.42 (0.38 – 0.59) vs. 0.46 (0.35 – 0.55), p=0.800) or the presence of Mallory-Denk 
bodies (0.46 (0.39 – 0.59) vs. 0.41 (0.34 – 0.56), p=0.111; Supplementary Figure 2a,c and 
Supplementary Figure 1c). 
None of the K18-M30 (1.14 kIU/L (0.89 – 3.73 vs. 2.32 kIU/L (1.08 – 3.64), p=0.331), K18-M65 
(3.48 kIU/L (2.10 – 7.04) vs. 5.11 kIU/L (3.15 – 7.76), p=0.250) or M30:M65 ratio (0.40 (0.35 – 
0.53) vs. 0.47 (0.39 – 0.59), p=0.141) differed significantly between cases defined by the presence 
or absence of megamitochondria (Supplementary Figure 1d-f) 
Circulating K18 fragments as diagnostic markers 
The utility of serum K18 fragments to predict definite histological ASH and the presence of severe 
inflammation was evaluated. Comparison was made with the white cell count as well as serum 
AST and ALT values as traditional markers of disease activity. 
The AUROC for K18-M65 for the prediction of ASH was 0.807 (95% Confidence Interval (CI): 
0.665 – 0.949) with K18-M30 demonstrating a similar predictive capacity (0.787 (95% CI 0.670 – 
0.903)). All of the K18-M30:M65 ratio, white cell count, serum ALT and AST demonstrated 
moderate to poor predictive capacity (Figure 2a). 
In the 79 cases with definitive ASH analysed, 60 (76%) had moderate inflammation with the 
remainder classified as severe. The AUROC for K18-M30 was 0.847 (95% CI: 0.749 – 0.945) 
whilst for K18-M65 it was 0.843 (95% CI: 0.742 – 0.943). None of the K18 M30:M65 ratio, white 
cell count, serum AST or ALT demonstrated reasonable performance in the prediction of severe 
inflammation (Figure 2b). 
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Evaluation of previously reported diagnostic thresholds 
Previous studies have reported a serum K18-M65 >2 kIU/L as having a high positive predictive 
value for the presence of ASH on biopsy in patients with clinically suspected AH(7). In the biopsy 
cohort included in histological analyses, K18-M65 >2 kIU/L had sensitivity and specificity of 85% 
and 50%, respectively for the presence of ASH. Accordingly, the PPV was 94% whilst the NPV 
was 25%. Conversely, serum K18-M65 levels <0.65 kIU/L were reported to have a high NPV for 
the presence of steatohepatitis. The lowest serum K18-M65 level in this cohort was 0.708kIU/L, 
thus the previously published lower cut-off was not assessed. 
When considered in the context of the entire cohort, 679/814 (83.4%) patients had a serum K18-
M65 value >2 kIU/L whilst only 2 individuals (0.25%) disclosed a serum K18 level <0.65 kIU/L. 
Consequently, using a serum K18-M65 <2 kIU/L but >0.65 kIU/L to define patients meeting clinical 
criteria for severe AH but requiring confirmatory liver biopsy would achieve an 84% reduction in 
the numbers requiring biopsy. 
In the control compensated (n=76) and decompensated (n=10) alcoholic cirrhosis cohorts, none 
had K18-M65 >2 kIU/L; levels were <0.65 kIU/L in 79/84; median was 0.119 kIU/L (IQR: 0.024-
0.213) in the compensated and 0.134 kIU/L (IQR: 0.042-0.225) in decompensated groups 
(Supplementary Table 2). 
Clinical correlates of serum K18 fragments 
Serum K18 fragments were not correlated with age (M30: rho=0.011, q=0.78; M65: rho=0.023, 
p=0.64, Supplementary Figure 3). Weak positive correlations were noted with baseline scores of 
liver dysfunction (MELD – M30: rho=0.21, q<0.01; M65: rho=0.24, q<0.01; DF – M30: rho=0.11, 
q<0.01; M65: rho=0.11, q<0.01) as well as the Lille score (Supplementary Figures 3 and 4). A 
modest correlation with serum AST level was noted for both the M30 (rho=0.22; q<0.01) and M65 
fragments (rho=0.27, q<0.01). Stronger correlations were seen with the circulating total white cell 
count (M30: rho=0.40, q<0.01; M65: rho=0.41, q<0.01) and the neutrophil count (M30: rho=0.43, 
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q<0.01; M65: rho=0.45, q<0.01). In contrast the M30:M65 ratio did not show strong correlations 
with any baseline clinicodemographic variables (Supplementary Figure 3).  
Analysis of prognostic associations of K18 fragments 
The association between serum K18 fragments and 90-day mortality was examined initially in 
prednisolone-untreated patients (n=417). The population treated with prednisolone (n=407) was 
used to validate these findings. The two cohorts were well matched for size, baseline 
demographics, including exposure to pentoxifylline, and outcomes (Supplementary Table 3). 
Serum K18-M30 (odds ratio (OR): 1.098, 95% CI 1.037 – 1.167, p=0.0016), K18-M65 (OR 1.060, 
95% CI 1.020 – 1.102, p=0.0032) and the M30:M65 ratio (OR: 6.35, 95% CI: 1.68 – 24.5, 
p=0.0064) were all significantly associated with 90-day mortality in prednisolone untreated 
patients. In multivariate analyses both the K18-M30 and K18-M65 demonstrated an association 
with mortality independently of age and MELD score (Table 2). This pattern of associations was 
also replicated for 28-day mortality (Supplementary Table 4). 
The associations of K18-M30 (OR: 1.080, 95% CI: 1.023 – 1.151, p=0.0126) and K18-M65 (OR: 
1.063, 95% CI: 1.025 – 1.107, p=0.0019) with 90-day mortality were replicated in prednisolone-
treated patients (Table 2). The M30:M65 ratio was not associated with 90-day mortality in the 
validation cohort (OR: 1.104, 95% CI: 0.223 – 4.897, p=0.899). When adjusted for age and MELD 
score K18-M65 retained independent significance. Again, the same pattern of associations was 
observed for 28-day mortality (Supplementary Table 4). 
Prediction of mortality 
In relation to 90-day mortality, the AUROC for K18-M30 was 0.626 (95% CI: 0.558 – 0.694) in the 
exploratory cohort and 0.616 (95% CI: 0.551 – 0.682) in the validation cohort (Figure 2c,d). Values 
for serum K18-M65 were similar with AUROCs of 0.629 (95% CI: 0.564 – 0.695) and 0.627 (95% 
CI: 0.563 – 0.692) in the exploratory and validation cohorts, respectively. By comparison the 
equivalent AUROCs for the MELD score were 0.710 (95% CI: 0.652 – 0.769) and 0.701 (95% CI: 
0.640 – 0.761) in the two cohorts. Scores combining the MELD score and either K18-M30 or K18-
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M65 demonstrated an incremental increase in the AUROC in the exploratory cohort (MELD-M30: 
0.722 (95% CI: 0.665 – 0.779; MELD-M65: 0.727 (95% CI: 0.660 – 0.775) (Figure 2c). A similar 
effect was seen in the validation population (MELD-M30: 0.706 (95% CI: 0.645 – 0.768); MELD-
M65: 0.711 (95% CI: 0.650 – 0.772)(Figure 2d). 
For 28-day mortality the analyses demonstrated similar results with AUROCs ranging from 0.634 
and 0.677 for K18 fragments alone (Supplementary Figure 5) compared to 0.718 – 0.791 for the 
MELD score. In both exploratory and validation cohorts the combination of MELD and K18 
fragments yielded a modest numerical improvement in the AUROC. 
Interaction testing with prednisolone 
In models assessing a multiplicative interaction, together with lower order effects, between either 
K18-M30 or K18-M65 and prednisolone the interaction terms were not significant (p=0.704 and 
p=0.925, respectively). Incorporation of a quadratic interaction between prednisolone and K18 
revealed significant interactions for both K18-M30 and K18-M65. Likelihood ratio testing indicated 
a significant improvement in fit with incorporation of the interaction terms (K18-M30: p=0.00437; 
K18-M65: p=0.00179). The interaction terms remained significant when the models were 
additionally adjusted for age and MELD (Table 3). No significant interaction was noted between 
the M30:M65 ratio and prednisolone either when modelled as a multiplicative or curvilinear effect 
(Supplementary Table 5, data not shown). Evaluation of predicted 90-day mortality risks as a 
function of serum K18 levels in patients treated with and without prednisolone demonstrated that 
at the lowest serum K18 levels prednisolone was associated with a trend towards an increased 
risk of death. At higher serum K18-M30 and M65 levels prednisolone therapy was associated with 
a reduced 90-day mortality risk (Figure 3a,b). Examination of prednisolone effect in sub-groups 
defined by serial K18 fragment cut-offs indicated no convincing separation in the confidence 
intervals for K18-M65 but an apparent divergence for K18-M30 at approximately 5 kIU/L (Figure 
3c,d). Accordingly prednisolone was associated with improved 90-day survival in those with serum 
K18-M30 >5 kIU/L but not those below this threshold (Figure 3e,f). Overall 104/814 (12.8%) of 
individuals displayed a serum K18-M30 >5 kIU/L. Examination of baseline demographics in groups 
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defined by this K18-M30 cut-off demonstrated a tendency to higher white cell and neutrophil 
counts as well as greater serum bilirubin and aspartate transaminase concentrations in the high 
K18-M30 group (Table 4). 
Comparison of high K18-M30 with Lille score as markers of prednisolone response 
The interaction terms were not significant in models assessing either multiplicative or curvilinear 
interactions between the Lille score and prednisolone therapy, irrespective of adjustment for age 
and baseline MELD score (Supplementary Table 6, data not shown). Consequently, prednisolone 
was not associated with 90-day mortality in either Lille responders or non-responders 
(Supplementary Figure 6a,b). 
Sequential evaluation of K18-M30 >5 kIU/L and Lille response to evaluate prednisolone efficacy 
was investigated. In individuals with a low serum K18-M30 (<5 kIU/L) there was no benefit from 
prednisolone in either Lille responders (OR 1.357, 95% CI 0.631 – 2.981, p=0.437) or non-
responders (OR 1.223, 95% CI 0.651 – 2.283, p=0.529), consistent with a lack of effect in the 
entire group (Supplementary Figure 6e,f). In the cohort of patients with K18-M30 >5 kIU/L 
prednisolone was associated with significant survival benefit in Lille responders (OR 0.143, 95% 
CI 0.0185 – 0.7313, p=0.0306) but not non-responders (OR 1.444, 95% CI 0.295 – 8.164, 
p=0.655, Supplementary Figure 6c,d). 
Influence of high K18-M30 on prednisolone-related infection risk 
In line with studies of the entire population, severe infections were more frequent in prednisolone-
treated patients in this subset of the STOPAH cohort (prednisolone: 48/407, 11.8% vs. no 
prednisolone: 29/417, 7.0%; OR: 1.789, 95% CI: 1.111 – 2.928, p=0.0182). Although a greater 
proportion of patients with K18-M30 >5 kIU/L experienced a severe infection (>5 kIU/L 13/104, 
12.5% vs. <5 kIU/L 63/710, 8.9%), there was no overall association between K18-M30 and the 
risk of severe infection (OR 1.015, 95% CI 0.965 – 1.055, p=0.471). No interaction was found 
between serum K18-M30 and prednisolone in relation to the development of severe infection 
(p=0.764). Accordingly, there was a greater prevalence of severe infections in prednisolone 
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treated patients in both the high (>5 kIU/L, 7/48 (14.6%) vs. 6/56 (10.7%)) and low K18-M30 
populations (<5 kIU/L, 40/353 (11.3%) vs 23/357 (6.4%)). All of these associations were robust to 
adjustment for age and baseline MELD score. 
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DISCUSSION 
AH is challenging to diagnose; a definitive diagnosis requires characteristic clinical and laboratory 
features with histological confirmation of steatohepatitis on liver biopsy(9). Given that, readily 
assayed serum biomarkers which aid diagnosis and prognostication would significantly aid clinical 
decision-making. Serum markers of hepatocellular death, in particular K18 fragments have shown 
promise as diagnostic markers in those with alcohol-related liver disease of varying severity (7, 
33). This study, conducted in a large number of patients with severe AH who participated in the 
STOPAH trial, helps to clarify a number of issues: i) serum K18 fragments are dramatically 
elevated in severe alcoholic hepatitis; ii) serum K18-M30 and M65 levels are strongly associated 
with the presence steatohepatitis and severity of inflammation on biopsy; iii) previously published 
thresholds for diagnosis performed well in this study – a K18-M65 level >2000 IU/L had a 94% 
PPV for the presence of steatohepatitis on biopsy; iv) K18 fragment levels also predict the 
presence of severe inflammation and are associated with outcome, independently of the severity 
of liver injury at presentation; v) serum K18-M30 is a likely theragnostic biomarker. 
Evaluation of the relationship between K18 fragments and prednisolone in relation to 90-day 
mortality indicates a curvilinear interaction with benefit restricted to those with higher serum K18 
levels and potential harm at the lower end of the spectrum (Figure 3c,d). In this cohort pre-
treatment serum K18-M30 exceeding 5 kIU/L defined a sub-group within which prednisolone 
conferred a 90-day survival benefit (Figure 3e). Below this threshold no therapeutic benefit was 
seen however an increased risk of severe infection remained indicating potential harm in the 
absence of therapeutic benefit (Figure 3f). These data are consistent with historical reports of 
harm associated with steroid therapy in patients with decompensated cirrhosis(34). Our data also 
suggest that K18-M30 guided prednisolone administration may be further refined through 
application of the Lille score with survival benefit apparently limited to responders. However, after 
case exclusion due to missing data and subdivision based upon Lille response the groups under 
evaluation in these analyses are small and the introduction of bias is likely. Thus, the results of 
these analyses should be confirmed in future studies. 
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In this cohort K18-M30/M65 values were markedly increased and often ≥10-fold higher than levels 
previously reported in healthy individuals(32, 35). Importantly K18-M30/M65 levels reported here 
substantially exceeded values reported in several chronic liver diseases including alcoholic 
cirrhosis, both in its compensated and decompensated state and were comparable with those 
observed in severe acute-on-chronic liver failure(19, 35, 36) and acute liver failure(37, 38). 
Serum K18 levels seem to be particularly elevated by alcohol exposure and the resulting liver 
injury. Accordingly, Macdonald et al detected significantly higher serum CK fragment levels in 
cirrhotics who had consumed alcohol in the preceding three months compared to those who had 
not(36). This observation is particularly interesting given that alterations of the keratin network with 
formation of Mallory-Denk bodies as well as so called “empty cells” devoid of any keratin staining 
are characteristic features of ASH(14, 39). Notably keratins constitute stress-inducible genes and 
their hepatic expression rises with severity of inflammation/injury(40).  
The study has a number of strengths. Recruitment of patients via a prospective multicentre trial 
permitted inclusion of a large number of patients with pre-determined inclusion criteria. 
Consequently, exploration and validation cohorts had a similar case mix and allocation to 
prednisolone therapy was entirely random, minimizing systematic bias. The key biomarkers were 
estimated in the overwhelming majority of the patient cohort. The AST:ALT ratio was >2 in most 
participants, in line with its proposed use as a diagnostic criterion for AH(31). The availability of 
systematically evaluated liver biopsies allowed us to demonstrate that serum K18 fragment levels 
are helpful in predicting both the presence of ASH and severity of inflammation, greatly exceeding 
that of the serum AST and ALT which are widely considered to be markers of disease activity. 
This corroborates recently published data(7, 33), and shows that K18 fragments constitute 
attractive non-invasive diagnostic markers of ASH. In contrast to the published studies which 
enrolled patients with varying severities of alcohol-related liver disease and comparatively small 
numbers of patients with severe alcoholic hepatitis, all patients included here met the diagnostic 
criteria for severe AH. Our finding that serum K18 fragments retain diagnostic, prognostic and 
potentially theragnostic associations in this more homogenous population with more severe 
22 
 
22 
 
 
disease underscores their relationship to disease activity and clinical utility. Application of 
previously defined thresholds to triage patients to biopsy in this population would result in a 
dramatic 84% reduction in the numbers requiring biopsy. Furthermore, this biomarker test can be 
completed within 24 hours of sampling. 
In line with the observed correlation of M30 and M65 with the histological severity of ASH, we 
detected an association between both biomarkers and 90-day mortality in both exploratory and 
validation cohorts. This is consistent with their prognostic abilities in individuals with acute liver 
failure, compensated and decompensated liver cirrhosis as well as in patients with alcohol-related 
liver disease(7, 16, 19, 33, 36-38). The somewhat limited prognostic accuracy of both biomarkers 
is likely due to the fact that they predominantly reflect only acute injury, and do not fully account 
for the extent of underlying liver fibrosis, which is also of prognostic importance(8). Because of 
this unique feature, K18-M30 and K18-M65 should be combined with markers reflecting cirrhosis-
associated liver failure. In that respect, the predictive power of K18-M30 and K18-M65 was 
independent of the MELD score and combination of these parameters resulted in a modest 
increase in the AUROC values. 
Given that prednisolone constitutes the only routine treatment option in AH, we were particularly 
interested to test whether the assessed markers of hepatocellular death predict the usefulness of 
this treatment. Notably, prednisolone administration was beneficial in individuals with K18-M30 >5 
kIU/L consistent with our observation that this cut-off is highly specific for AH patients with severe 
inflammation. Application of this cut-off in clinical practice could restrict prednisolone usage to 
around 13% of patients – maximizing benefit whilst dramatically reducing the risk of steroid-related 
complications. 
This study has limitations. Importantly, the use of a trial population means that findings from this 
study cannot be readily generalized to individuals who do not match this patient population. In 
particular, some individuals with the most profound organ failure were excluded from the STOPAH 
trial(26). Interaction modelling indicates a potential window for prednisolone benefit, however large 
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confidence intervals and a fall in the predicted mortality risk for untreated individuals at the higher 
extremes of serum K18 levels likely reflects a combination of the limits of the parametric model 
and poor calibration at these levels. Our search for a therapeutic cut-off using the same data in 
which the interaction models were fitted means that the value generated is likely over-fitted and 
requires validation in a further cohort. Evaluation of the temporal evolution of serum K18-M30 
fragments, as a marker of prednisolone response in treated patients or marker of deterioration in 
untreated patients, would provide additional support for use of K18-M30 as a theragnostic marker 
and warrants investigation in future studies. 
In conclusion, our data indicate the potential applications of K18-M30 and K18-M65 as biomarkers 
in severe AH. The ability to predict the presence of steatohepatitis on biopsy seen here and the 
validation of findings from prior studies indicates that K18-M65 should be considered for adoption 
into clinical practice as a diagnostic adjunct. Additionally, K18 has prognostic utility, independently 
of the MELD score. Finally, K18 may act as a theragnostic biomarker, guiding triage to 
prednisolone therapy though validation in an independent cohort is desirable. Considering the 
large groups of patients involved and use of independent exploratory and validation cohorts, 
serum K18 estimation should be adopted into routine clinical practice as it identifies patients with 
severe alcoholic hepatitis, especially those who benefit from steroid therapy, without the need to 
perform a liver biopsy. 
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TABLES 
Table 1: Baseline demographics of populations based upon biopsy status. 
Variable 
median (interquartile range) or 
‘n’ (%) 
Biopsy-cohort 
(n=87) 
Non-biopsy cohort 
(n=737) 
Age (years) 47.0 (42.5 – 53.8) 49.1 (41.9 – 56.6) 
Sex (male) 60 (69%) 460 (62%) 
Alcohol (units/week) 120 (84 – 196) 132 (84 – 210) 
Encephalopathy   
 Grade 0 61 (72%) 522 (74%) 
 Grade 1 21 (25%) 123 (17%) 
 Grade 2 2 (2%) 42 (6%) 
 Grade 3 1 (1%)16 (2%) 16 (2%) 
Mortality at 90 days 15 (17%) 179 (24%) 
Haemoglobin (g/L) 106 (95 – 118) 107 (94 – 120) 
White cell count (x106/mm3) 9.5 (6.2 – 12.3) 8.5 (6.1 – 12.3) 
Neutrophils (x106/mm3) 6.5 (3.9 – 9.6) 6.0 (4.1 – 9.6) 
Bilirubin (µmol/L) 319 (192 – 452) 258 (161 – 401) 
ALT (IU/L) 42 (29 – 53) 42 (30 – 61) 
AST (IU/L) 120 (85 – 153) 115 (85 – 158) 
Albumin (g/L) 26 (22 – 30) 25 (21 – 29) 
Urea (mmol/L) 3.6 (2.5 – 6.5) 3.2 (2.2 – 5.1) 
Creatinine (µmol/L) 69 (58 – 102) 63 (51 – 82) 
INR 1.7 (1.5 – 2.0) 1.8 (1.6 – 2.1) 
DF 56 (41 – 77) 55 (43 – 74) 
MELD 24 (21 – 28) 23 (21 – 26) 
K18-M30 (kIU/L) 1.98 (0.91 – 3.65) 1.81 (0.97 – 3.35) 
K18-M65 (kIU/L) 4.87 (2.54 – 7.44) 4.36 (2.53 – 6.74) 
K18-M30:M65 ratio 0.43 (0.36 – 0.57) 0.45 (0.39 – 0.53) 
 ALT, alanine transaminase; AST, aspartate transaminase; INR, International Normalised Ratio; 
DF, Maddrey’s discriminant function; MELD, Model for End-stage Liver Disease score; K18, 
keratin-18. 
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Table 2. Logistic regression analyses for serum K18 fragments in relation to 90-day mortality 
 Exploratory (- prednisolone) Validation (+ prednisolone) 
 Univariate Analysis 
 OR* 95% CI p OR* 95% CI p 
K18-M30 (kIU/L) 1.098 1.037 – 1.167 0.0016 1.080 1.023 – 1.151 0.0126 
K18-M65 (kIU/L) 1.060 1.020 – 1.102 0.0032 1.063 1.025 – 1.107 0.0019 
M30:M65 ratio 6.354 1.682 – 24.46 0.0064 1.104 0.223 – 4.897 0.8989 
 Multivariate Analysis for K18-M30 
Age (years) 1.038 1.013 – 1.065 0.0036 1.097 1.065 – 1.131 <0.001 
MELD (points) 1.202 1.132 – 1.283 <0.001 1.166 1.106 – 1.233 <0.001 
K18-M30 (kIU/L) 1.080 1.020 – 1.147 0.0092 1.059 1.000 – 1.137 0.0962 
 Multivariate Analysis for K18-M65 
Age (years) 1.039 1.014 – 1.066 0.0025 1.097 1.066 – 1.132 <0.001 
MELD (points) 1.199 1.129 – 1.280 <0.001 1.162 1.102 – 1.229 <0.001 
K18-M65 (kIU/L) 1.044 1.000 – 1.090 0.0438 1.0000 1.008 – 1.100 0.0278 
*Odds ratios (OR) are quoted per 1 unit increase in the predictor variable. For K18-M30 and -M65 
the ORs are per 1 kIU/L increase in serum concentration, for age it is per additional year and 
MELD score per whole point increase. For K18 M30:M65 ratio the OR is quoted per whole number 
increase. 
K18, keratin-18; OR, Odds Ratio; CI, confidence interval; MELD, Model for End-stage Liver 
Disease score.   
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Table 3. Logistic regression interaction analyses for serum K18-M30 and K18-M65 with 
prednisolone in relation to 90-day mortality. 
Model A: Interaction between prednisolone and K18-M30 
 OR* 95% CI p 
Prednisolone 1.498 0.842 – 2.703 0.174 
K18-M30 (kIU/L) 1.305 1.132 – 1.537 0.0006 
K18-M302 1.000 1.000 – 1.000 0.0281 
Age (years) 1.066 1.046 – 1.087 <0.0001 
MELD 1.171 1.125 – 1.221 <0.0001 
Prednisolone:K18-M30 0.814 0.675 – 0.965 0.0237 
Prednisolone:K18-M302 1.000 1.000 – 1.000 0.0397 
 
Model B: Interaction between prednisolone and K18-M65 
 OR 95% CI p 
Prednisolone 1.806 0.812 – 4.138 0.154 
K18-M65 (kIU/L) 1.286 1.114 – 1.501 0.0009 
K18-M652 1.000 1.000 – 1.000 0.0068 
Age (years) 1.065 1.045 – 1.085 <0.0001 
MELD 1.168 1.122 – 1.218 <0.0001 
Prednisolone:K18-M65 0.830 0.698 – 0.978 0.0300 
Prednisolone:K18-M652 1.000 1.000 – 1.000 0.0160 
K18, keratin-18; OR, Odds Ratio; CI, confidence interval; MELD, Model for End-stage Liver 
Disease score. *Odds ratios (OR) are quoted per 1 unit increase in the predictor variable. For K18-
M30 and -M65 the ORs are per 1 kIU/L increase in serum concentration, for age it is per additional 
year and MELD score per whole point increase. For K18 M30:M65 ratio the OR is quoted per 
whole number increase. 
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Table 4: Baseline demographics of populations defined by serum K18-M30 above or below 5 
kIU/L. 
Variable Median (interquartile range) or 
‘n’ (%) 
Low K18-M30* 
(n=710) 
High K18-M30* 
(n=104) 
Age (years) 48.8 (41.8 – 56.1) 49.5 (43 – 57.1) 
Sex (male) 449 (63%) 65 (62%) 
Alcohol (units/week) 130 (85 – 208) 140 (84 – 210) 
Pentoxifylline 355 (50%) 54 (52%) 
Encephalopathy    
 Grade 0 499 (73%) 76 (78%) 
 Grade 1 129 (19%) 14 (14%) 
 Grade 2 38 (6%) 5 (5%) 
 Grade 3 15 (2%) 2 (2%) 
Ninety-day mortality 145 (20%) 46 (44%) 
Haemoglobin (g/L) 107 (94 – 120) 103 (93 – 119) 
White cell count (x106/mm3) 8.2 (5.9 – 11.7) 12.6 (8.8 – 14.8) 
Neutrophils (x106/mm3) 5.7 (3.9 – 9.9) 9.8 (6.1 – 12.1) 
Bilirubin (µmol/L) 260 (158 – 403) 320 (205 – 420) 
ALT (IU/L) 41 (29 – 61) 46 (30 – 61) 
AST (IU/L) 114 (85 – 154) 141 (107 – 177) 
Albumin (g/L) 25 (21– 29) 26 (22 – 30) 
Urea (mmol/L) 3.1 (2.1 – 5.0) 4.7 (2.9 – 8.0) 
Creatinine (µmol/L) 63 (52 – 80) 74 (55 – 101) 
INR 1.8 (1.6 – 2.0) 1.8 (1.5 – 2.1) 
DF 55 (43 – 73) 59 (46 – 77) 
MELD 23 (21 – 26) 24 (22 – 28) 
K18-M30 (kIU/L) 1.42 (0.89 – 2.65) 9.27 (6.91 – 12.2) 
K18-M65 (kIU/L) 3.82 (2.34 – 5.82) 14.2 (9.85 – 20.7) 
K18-M30:M65 ratio 0.43 (0.37 – 0.51) 0.66 (0.55 – 0.79) 
*High K18-M30 defined as serum K18-M30 >5 kIU/L 
ALT, alanine transaminase; AST, aspartate transaminase; INR, International Normalised Ratio; 
DF, Maddrey’s discriminant function; MELD, Model for End-stage Liver Disease score; K18, 
keratin-18. 
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FIGURE LEGENDS 
Figure 1. Levels of serum K18-M30 and K18-M65 in patients with different histological Laenec 
fibrosis grades (a,b), inflammation severities (c,d) and hepatocyte ballooning severities (e,f) 
according to the alcoholic hepatitis histological scoring system (AHHS). Data are displayed as the 
median (solid bar), interquartile range (box) and 95% confidence interval (whiskers).  
Figure 2. Receiver operating characteristic (ROC) curves for the confirmation of histological 
alcoholic steatohepatitis (ASH) in patients with clinically diagnosed alcoholic hepatitis (a) and the 
presence of severe inflammation in patients with clinically diagnosed alcoholic hepatitis and ASH 
on biopsy (b). ROC curves for the prediction of ninety-day mortality by serum K18 fragments alone 
or combination with the MELD score in patients with clinically diagnosed alcoholic hepatitis and 
treated without (c) or with (d) prednisolone. 
Figure 3. Plots illustrating predicted 90-day mortality risk in patients treated with and without 
prednisolone implied by the interaction models for (a) serum K18-M65 and (b) serum K18-M30, 
values adjusted for Model for End-stage Liver Disease (MELD) score and age. Estimates for 
prednisolone efficacy when dichotomizing the population across a range of (c) K18-M65 and (d) 
K18-M30 values. Kaplan-Meier survival functions illustrating the effect of prednisolone treatment 
in populations defined by a serum K18-M30 above (e) or below (f) 5 kIU/L. 
Data are displayed as estimated mortality risk (solid line) with 95% confidence intervals (dashed 
line and shaded area) with (blue) and without (red) prednisolone therapy. 
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